The potential effects of deploying SARS-Cov-2 vaccines on cold storage capacity and immunization workload in countries of the WHO African Region
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
-
SciScore for 10.1101/2020.08.13.20147595: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:The impact on cold storage and workforce is also likely to be reduced by SARS-CoV-2 vaccine supply limitations, as WHO is currently planning for an initial tranche of vaccines to cover 3% of a country’s population [34]. With sufficient planning and resources, success could be achieved for SARS-CoV-2 vaccination programs targeting much …
SciScore for 10.1101/2020.08.13.20147595: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:The impact on cold storage and workforce is also likely to be reduced by SARS-CoV-2 vaccine supply limitations, as WHO is currently planning for an initial tranche of vaccines to cover 3% of a country’s population [34]. With sufficient planning and resources, success could be achieved for SARS-CoV-2 vaccination programs targeting much higher proportion of a country’s population. A SARS-CoV-2 vaccination campaign would be greatly facilitated if vaccine delivery were simplified [21]. While a one dose vaccine would be ideal, initial Phase 1 data indicate that two doses will likely be needed [2]. Nasal spray or transdermal patch vaccines that could be administered by trained lay persons would free skilled health workers to provide other essential services, but no such vaccines are currently in human trials [1]. While single dose vial vaccine presentations limit vaccine wastage [4, 20], and prefilled syringe presentations limit wastage and greatly simplify administration [20], their cold storage volumes per dose make these presentations highly problematic for use in mass vaccination campaigns in the African Region. For influenza vaccines (our proxy for SARS-CoV-2 vaccines in this analysis), secondary and tertiary packaging volumes per dose for multidose vials (5.4 mL and 7.2 mL) [17] are much lower than for single dose vials (median of WHO prequalified products: 18.4 mL and 87.3 mL) [17] and prefilled syringes (Flublok® Quadrivalent: 86.5 mL and 111.8 mL) (personal communication G...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-